Astra’s first attempt fails, but there’s no giving up on KRAS
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
Sillajen and Transgene bid to revive the oncolytic virus craze
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Are the big corporate venture arms retreating?
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Regeneron and Sanofi play follow the leader on Praluent pricing
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
Lilly hopes volume can make up for late migraine entry
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
The list of shame no biopharma wants to join
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Roche dominates 2019’s big patent expiries
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.